Premium
Influence of MDM2 and MDM4 on development and survival in hereditary retinoblastoma
Author(s) -
de Oliveira Reis Adriana Helena,
de Carvalho Ivéria Silva Ribamar,
de Sousa Damasceno Paula Batista,
Ferman Sima Esther,
Lucena Evandro,
LopezCamelo Jorge Santiago,
Seuánez Héctor N.,
Vargas Fernando Regla
Publication year - 2011
Publication title -
pediatric blood and cancer
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.116
H-Index - 105
eISSN - 1545-5017
pISSN - 1545-5009
DOI - 10.1002/pbc.24014
Subject(s) - retinoblastoma , medicine , mdm2 , allele , malignancy , oncology , cancer , genetics , gene , biology
Background Retinoblastoma (RB) accounts for 3% of all childhood malignancies, with different incidences around the world. This malignancy results from loss‐of‐function of both RB1 alleles although other genes, like MDM2 and MDM4 , have been proposed to be involved in tumor development. Procedure We genotyped rs2279744T>G and rs937283A>G in MDM2 , and rs4252668T>C and rs116197192G>A in MDM4 , in 104 unrelated RB patients and 104 controls. Sixty‐month survival Kaplan–Meier curves and χ 2 ‐tests were performed for estimating the putative effect of MDM2 and MDM4 alleles on disease progression and survival of RB patients. Results MDM2 rs2279744G was significantly more frequent in controls, indicating an apparently protective effect on RB development. However, survival of patients who carried a constitutional RB1 mutation was significantly lower with rs2279744TG or GG than with rs2279744TT. Presence of rs2279744G and a constitutional RB1 mutation was sixfold more frequent in the 0–12 month age group than other age groups at onset of symptoms ( P = 0.0401). MDM4 rs4252668C was present at a significantly higher frequency in controls while the frequency of MDM4 rs116197192G was significantly higher in RB patients, suggesting that this allele might increase the risk of developing RB. Conclusion Our results indicate that MDM2 and MDM4 polymorphisms may influence development and/or survival in RB. Pediatr Blood Cancer 2012; 59: 39–43. © 2011 Wiley Periodicals, Inc.